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Summary Fifteen patients with locally advanced refractory breast cancer have been treated with recombinant
leucocyte interferon (rIFN-aA) for up to 12 weeks. Toxicity was considerable with the initial dosage schedule
employed but became acceptable after reducing the starting dose by 50%. Minor side effects occurred in all
patients and major CNS toxicity in six. Nine patients showed some evidence of tumour regression at 4 weeks.
Only two of these were still responding at 12 weeks. Response was unrelated to the length of previous history,
oestrogen receptor status or previous responsiveness to cytotoxic or hormone therapy.
Interferon has been the subject of scientific interest
for over 20 years, first as an antiviral agent and
later as an anticancer drug. Early preparations were
produced by challenging cells in tissue culture with
inducing agents such as viruses or synthetic RNA
(Gresser, 1961). Three main cell types were used.
Leucocytes derived from buffy coats, or from
leukopheresis preparations, produced crude a-
interferon of 0.1% purity which could be partially
refined by precipitation methods (Cantell et al.,
1981; Horowitz, 1981). Human lymphoblastoid cell
lines derived from patients with Burkitt's
lymphoma resulted in a mixture of a and y-
interferon (Strander et al., 1975). Normal
fibroblasts grown in tissue culture resulted in /B-
interferon of higher specific activity (Giard et al.,
1979). It has gradually become clear that there are
at least 3 gene families of inferferons: a, mainly
derived from leucocytes, P from fibroblasts, and
y-interferon produced by mitogen or antigen
stimulated lymphocytes.
With the advent of the recombinant DNA
technology it is possible to produce vast quantities
of interferon of high specific activity by genetic
engineering. Human interferon genes have been
isolated and cloned in bacterial plasmids (Goeddel
et al., 1980). The recombinant plasmids are
inserted into E. coli, where they can replicate and
produce mRNA, which in turn causes the bacterial
protein synthesis machinery to make human
interferon. Clones of E. coli have been isolated
which produce large amounts of interferon. Using
industrial fermentation techniques, unlimited
quantities of interferon are now available for
clinical use. There may be biochemical differences,
such as the absence of glycosylation, between
recombinant and natural interferons but the
significance of these differences is not known.
Until recently clinical studies have used crude
interferons of low purity. Profound side effects were
observed which were initially attributed to
impurities (Armin et al., 1983). Furthermore, the
inadequate supplies and difficulties in purification
allowed only limited amounts of interferon to be
used. Nevertheless there was a wealth of data
showing regression of animal tumours (Gresser,
1977) and cytotoxic activity against tumour cell
lines (Gresser, in press). In addition there were
encouraging reports of tumour regression in
patients with myeloma, non-Hodgkin's lymphoma,
breast cancer, melanoma, renal carcinoma and
Kaposi's sarcoma (Sikora, 1983). In patients with
advanced breast cancer, 30% partial remission rates
were reported by two groups using crude buffy coat
interferon (Gutterman et al., 1980; Borden et al.,
1980).
These preliminary results, together with the
availability of large amounts of highly purified
recombinant interferon, led us to set up a phase II
study to look at the use of one preparation,
recombinant leucocyte A interferon (rIFN-aA,
Hoffman-La Roche) in patients with advanced
breast cancer.
Patients and methods
Fifteen patients with readily assessable disease were
studied. Those with CNS metastases, malignant
pleural effusions, ascites, blastic or mixed
lytic/blastic osseous metastases as the only evidence
of disease were excluded. Also excluded were
patients with hypercalcaemia or impaired
haematological, renal or hepatic function.
Treatment with non-steroidal anti-inflammatory
agents was not permitted during the study,
Corticosteroid doses were no greater than
physiological replacement. No anti cancer
medication (hormones or chemotherapy) was given
for the 4 weeks preceding the study. The dose of
rIFN-ocA was randomised to 20 x 106 units m-2 daily
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or 50 x 106m-2 3 times weekly by deep i.m.
injection for 12 weeks. It was initially planned to
study 60 patients but the study was stopped at 15
in view of the poor response rate. This dose was
based on previously reported phase I studies
(Gutterman et al., 1982). Dose reductions to 50%
and then 10% of the above doses were made in
patients with toxic side effects. All patients were
aware of their diagnosis and gave written informed
consent to the study.
Patients were assessed on entry by full clinical
examination, chest X-ray, bone scan, liver function
tests, and photography of skin lesions. These
investigations were repeated periodically during
IFN therapy. Oestrogen receptor status was also
determined on a repeat biopsy, performed under
local anaesthetic in all patients. Patients were
admitted to hospital for initiation of IFN therapy
but in most cases were discharged after several
days. A community research nurse continued
outpatient treatment and provided a crucial link
between the patient's home and the clinic. Patients
were formally assessed by two of us at regular
intervals for signs of tumour regression, toxicity
and performance status. A disease marker, such as
a lymph node or patch of skin infiltration which
could be measured, was chosen as an indicator for
response. The following criteria were used: (CR) for
disappearance of all tumour; partial response (PR)
for 50% reduction in the product of the longest
perpendicular diameters; stable disease where no
change occurred; or progressive disease when
tumour growth continued unabated. We also used
the term less than partial response (LPR) for a
response not satisfying the criterion for PR. Clinical
photographs were taken frequently since the
measurement of extensive infiltrative or ulcerative
chest wall disease by the above criteria was often
difficult.
Toxicity was graded as in Table II and dose
reductions made to 50% of the planned dose for
two or more minor toxicities; to 10% if moderate
toxicity was observed. The appearance of a major
toxic effect resulted in the discontinuation of IFN
until the effect disappeared.
Results
The ages of the 15 patients ranged between 41 and
69 (mean 60). All were post menopausal and all
had received previous treatment with one or more
of the following: hormones, radiation, cytotoxic
therapy (combination therapy or oral
cyclophosphamide). All had progressive disease at
the time of entry. Four had lymph node recurrences
and the remaining eleven more widespread chest
wall disease which was fungating or ulcerated in 4
patients. Three patients had pleural effusions and
one pulmonary secondaries. Ten patients had
positive bone scans.
In the first 11 patients treated, drastic dose
reductions to 10% of the initial dose were necessary
in all but one on account of lethargy and CNS
toxicity. In the last 4 patients whose starting dose
was reduced by 50% (10 x 106unitsm-2 daily or
25 x 106unitsm-2 3 times weekly) only one further
small dose reduction was necessary in one patient.
There were no obvious differences in toxicity
between daily or 3 times weekly administration.
Four patients died during IFN therapy. In 2 of
these death was possibly related to the treatment,
either resulting from direct CNS toxicity or
secondary to dehydration and renal failure which
followed as a result of impaired cerebration. Two
deaths occurred in patients with very advanced
carcinomatosis and were considered disease-related.
Side effects
CNS All patients experienced varying degrees of
lethargy, anorexia, nausea, vomiting, headache and
myalgia. Five developed transient paraesthesia.
Severe lethargy preceded a dose related state of
confusion, disorientation, and dysphasia, if regular
IFN administration continued. Subsequent coma
developed in the two patients whose deaths were
possibly related to IFN therapy. No predisposing
metabolic cause could be found for these deaths
and there was no evidence of cerebral metastases.
Severe CNS side effects were seen in 6 patients
(Smedley et al., 1983). Serum electrolytes, glucose
and liver function tests remained unchanged during
this syndrome. EEGs showed excess slow wave
activity and in subsequent patients serial EEGs
showed increasing slow wave activity as interferon
therapy progressed despite the absence clinically of
major CNS toxicity. The EEG abnormalities
improved slowly after stopping treatment in the
patients who have been reassessed at this stage. All
four patients treated on the reduced dosage
developed EEG slow wave changes although none
developed major CNS toxicity. CNS toxicity
appeared, therefore, to be dose related. There was
no major toxicity for doses <10x 106unitsm-2
daily.
Weight loss Nearly all patients lost weight and in
some this was 10% or more of body wt. Weight
loss resulted from anorexia, nausea, vomiting as
well as the total loss of interest in sustenance and
self preservation during periods of extreme lethargy
and fatigue.
Haematological Nine patients showed a small fall
in haemoglobin levels at 4 weeks. All but 2 patientsRECOMBINANT INTERFERON IN BREAST CANCER 617
showed a fall in the white cell count which occurred
within the first 3 weeks and thereafter returned to
near normal levels. The mean count fell from
6.6 x 1091-1 initially to 2.9 x 1091 1. There were no
infections resulting from leukopenia and a
neutrophilia occurred in two patients in response to
infection (one chest infection and one case of
cystitis). The platelet count fell in parallel with the
white cell count, mean values falling from
315+101 x 1091-1 to 178+100x 1091-1. Two
patients who had received extensive chemotherapy
developed counts below 100 x 1091- but there were
no purpuric or haemorrhagic complications.
Hepatic The bilirubin and alkaline phosphatase
levels did not appreciably alter during IFN therapy
except in patients with progressive disease. The
SGPT (L-alanine, 2-oxogluterate aminotransferase)
rose in the second to third week in all patients and
then returned slowly to normal. It appeared
unrelated to major CNS toxicity and its significance
is unknown (Table I).
Table I Mean SGPT levels (iu.I-')
Initial 24+8a
Week 1-2 62+23
Week 3-4 35+14
Week 6-12 28+7
as.d.
Fever All patients developed pyrexia shortly after
commencing IFN. This was easily controlled by
paracetamol and settled within one week.
In order to assess the severity of the side effects
we have classified them as major, moderate and
mild (Table II) and recorded the proportion of time
during IFN therapy that each patient suffered these
side effects. Finally we have averaged the
percentages over all patients (Table III). It is clear
that by reducing the starting dose to
10 x 106units m2 daily major toxicity was avoided,
but that one-third of patients still had moderate,
and two-thirds mild toxicity. The absence of a "no
toxicity" category in this group is due to the fact
that at this dose IFN therapy could continue
whereas for the first 11 patients the treatment was
frequently reduced to 3 x 106units daily (or
equivalent) after about 4 weeks, or stopped
temporarily, and not restarted untill all toxic side
effects had completely subsided.
We also looked at the time spent in hospital
during IFN therapy. Ten patients were able to go
home 2 days after starting treatment and only 3 of
these needed readmission. The average time spent
in hospital was 13 days with a range from 2 to 45
D
Table H Toxicity ofinterferon
(One symptom alone is sufficient to qualify for appropriate
category)
Major: Confusion
Disorientation
Dysphasia
Coma
Moderate: Severe lethargy: sleeping up to 20h per day
Severe anorexia
Severe nausea
Intractable vomiting
Mild: Lethargy
Anorexia
Nausea and vomiting
Pyrexia
Headaches
Myalgia
Parasthesia
Table III Time spent with each of the above toxicities
expressed as a percentage ofthe total time receiving IFN
No Mild Moderate Major
toxicity toxicity toxicity toxicity
Patients 1-11 7% 59% 29% 5%
Patients 12-15 0 68% 32% 0
days. The Karnofsky status was assessed weekly
and the median value of 90 (range 70-100) prior to
IFN fell to 60 (range 30-80) during therapy.
Tumour response
In the assessment of any new form of cancer
treatment the odds are loaded heavily against the
new modality in that patients must, for ethical
reasons, have very advanced disease. Despite the
severe toxicities encountered, we found that many
patients were reluctant to stop therapy. Tumour
regression was seen in lymph nodes, skin
infiltration and ulcerated and fungating lesions.
Arm lymphoedema also lessened on objective
measurement. Analgesic requirements decreased in
3 patients with painful bone metastases and in one
of these the serum alkaline phosphatase level fell.
We also noted a phenomenon observed in other
studies - regression of disease at one site with
progression elsewhere.
Of the 12 patients assessed at 4 weeks, 2 were
considered to have had true partial responses,
and 7 less than partial responses. One patient had
stable disease and one had disease progression. The
remaining patient had a partial response at the618 A. NETHERSELL et al.
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indicator site but developed on going disease in the
opposite breast. At 12 weeks, or cessation of
therapy, 10 patients were alive. There were only 2
who showed any degree of response at this stage,
the others having relapsed. It should be noted,
however, that the dose of IFN administered for the
last 8 weeks in most patients was much lower than
for the first month.
We have explored whether there were any
obvious predisposing factors governing response
(Table IV). Here we tabulate age, oestrogen
receptor (ER) status and the number of months
from presentation to first relapse as well as the time
between this relapse and starting IFN therapy. This
indicates the natural history and aggressiveness of
the disease process for each patient. We have also
summarised response to previous cytotoxic or
hormone therapy in an attempt to see whether any
patterns of responsiveness emerge.
Other independent variables governing response
are the dose of IFN used and the duration of
therapy. Many patients had a dose reduction after
4 weeks. We have stated the mean dose of IFN
given per week during the first 4 weeks and the
subsequent weeks respectively for each patient. The
responses at 4 and 12 weeks are presented as well
as survival.
Discussion
Response could not be related to the total duration
of previous history, previous response to hormones
or cytotoxic drugs, oestrogen receptor status or the
dose of IFN administered. In the two patients who
were still responding at 12 weeks, two factors
emerge. Firstly, each patient had very advanced
local disease without obvious metastases. The first
patient had disease for 46 months from diagnosis
and probably for 3 years prior to this. She had
shown some improvement with tamoxifen. Clearly
she had lived in symbiosis with her disease for a
long time. The second patient had presented with a
locally fungating carcinoma which she admitted
having had for well over a year and we suspect
much longer. There had been little response to 5
months tamoxifen therapy but equally little
progression. In both cases the relative indolence of
the disease could have been a function of the
disease itself (i.e. mitotic rate) or of immunological
factors in the host, or both. It is interesting,
however, that both these patients showed the most
consistent and sustained response to IFN. Little is
known of the possible antitumour activity of IFN
in vivo. Possible mechanisms include the inhibition
of DNA-replication in the malignant cell following
Table V Average weekly dose rIFN-aA given
during study
First month Subsequent
Average for patients
1-11 194+62 86+76
Average for patients
12-15 123+21 134+11
Value for patient
4 217 258
Value for patient
14 126 126
membrane binding or
immune svstem.
stimulation of the host's
The second feature common to these two patients
is that they completed 12 weeks of IFN treatment
with relatively few toxic side effects and
consequently with little dose reduction. To explore
this further we have calculated the average weekly
doses of IFN for the groups of patients 1-11 and
12-15 for the first month of IFN therapy, and
subsequently, and compared these with the two
responding patients (Table V). There was a marked
dose reduction after one month owing to toxicity in
the first 11 patients and this was overcome by
reducing the starting dose. Patient 4 tolerated a
dose which was far higher than the 12 week average
for the other patients, and tumour regression may
have been dose related. The dose of patient 14 was
no different from the other 3 patients in her group
who failed to respond, and not very different from
the dose used in many of the first 11 patients. It
seems unlikely, therefore, that her response was
dose related. Patient 4 went on to maintenance IFN
for one year, 86 x 106 units twice weekly. She has
suffered no appreciable toxicity but has required
additional treatment in the form of local irradiation
and oral cytotoxic therapy. The response of her
tumour to radiation has been excellent. Her EEG
has showed persistent slow wave activity but has
not significantly altered over the year.
The study would suggest that there is little place
for rIFN-axA as a single agent in breast cancer
although this study did not investigate its role in
combination with other agents or as an adjuvant.
There is no doubt, however, that many patients
showed signs of tumour destruction at 4 weeks. The
objective responses seen however encourage further
study to investigate the potential value of IFN and
its mechanism of action which are currently
unknown. We also noted several responses to
irradiation which were unexpectedly good in620 A. NETHERSELL et al.
patients who were receiving, or had recently
received, IFN. We are currently looking into this
possible synergism, encouraged by the fact that
others have made similar observations in relation to
chemotherapy and interferon.
We thank Drs S. De Garis, Z. Dziewanowska, and I.
Lenox-Smith of Hoffmann-La Roche for their helpful
advice, Hoffman-La Roche for providing the interferon,
and our colleagues for referring patients for this study.
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